Angiotensin II in Liver Transplantation

Running, not enrolling · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Liver Transplant; Complications, Vasoplegia

In brief

The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.

Key facts

Study ID

NCT04901169

Run by

University of California, San Francisco

People needed

50

Starts

2022-06-28

Expected to finish

2027-03-18

Last updated by the study team

2026-03-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > or = 18 years
• Liver transplantation from a deceased donor
• Model for End-stage Liver Disease Sodium (MELD-Na) score > or = 25 at the time of transplant (not counting MELD exception points)
• Patient requiring > 0.05 mcg/kg/min of norepinephrine (NE) during LT

You may not qualify if…

• Living-donor liver transplantation (LDLT)
• Split liver transplantation (isolated right or left lobe)
• Donation after cardiac death (DCD) without normothermic machine perfusion (NMP)
• Acute liver failure (ALF)
• Listed for or receiving simultaneous liver-kidney transplantation (SLKT)
• Liver re-transplantation (patient who has previously received a liver transplant)
• Preoperative treatment with angiotensin II receptor blocker or angiotensin converting enzyme inhibitor (within 48 h)
• Portopulmonary hypertension
• Left ventricular systolic dysfunction (defined as ejection fraction < 45%)
• Active bronchospasm at time of LT
• History of thrombotic or embolic disease, inherited hypercoagulable disorder, or therapeutic anticoagulation
• Portal vein thrombosis
• Celiac stenosis
• End-stage renal disease (chronic eGFR < 15 mL/min/1.73 m2 or chronic RRT - not including AKI requiring RRT)
• History of Raynaud's disease
• Known history of allergy to synthetic human angiotensin II
• Subject intubated and/or mechanically ventilated prior to entering OR for LT
• Presence of other condition or abnormality that would compromise the safety of the patient or quality of the data

Where it is running

• University of California, San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.